Posaconazole salvage therapy: The Posifi study

Posaconazole (PCZ) is used mainly for the prevention of invasive fungal infection (IFI).

[1]  Versione,et al.  Common Terminology Criteria for Adverse Events , 2020, Definitions.

[2]  D. Kontoyiannis,et al.  Tolerability of isavuconazole after posaconazole toxicity in leukaemia patients , 2018, Mycoses.

[3]  D. Kontoyiannis,et al.  411. Tolerability of Isavuconazole After Posaconazole Toxicity in Leukemia Patients , 2018, Open Forum Infectious Diseases.

[4]  C. Beigelman-Aubry,et al.  Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. , 2018, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[5]  C. Jordá,et al.  Salvage therapy with topical posaconazole in lung transplant recipients with invasive Scedosporium infection , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[6]  B. Alexander,et al.  Changing Epidemiology of Invasive Mold Infections in Patients Receiving Azole Prophylaxis. , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  L. Pagano,et al.  ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients , 2016, Haematologica.

[8]  P. Hamal,et al.  Successful Posaconazole Therapy of Disseminated Alternariosis due to Alternaria infectoria in a Heart Transplant Recipient , 2017, Mycopathologia.

[9]  Jong Hun Kim,et al.  Utilization of posaconazole oral suspension or delayed‐released tablet salvage treatment for invasive fungal infection , 2016, Mycoses.

[10]  D. Denning,et al.  Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  黄亚明,et al.  European Society of Clinical Microbiology and Infectious Diseases , 2016 .

[12]  J. Perfect,et al.  Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. , 2016, The Lancet. Infectious diseases.

[13]  H. Waskin,et al.  Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease. , 2016, The Journal of antimicrobial chemotherapy.

[14]  J. Baddley,et al.  Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial , 2016, The Lancet.

[15]  J. Pemán,et al.  Breakthrough candidaemia in the era of broad-spectrum antifungal therapies. , 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[16]  G. Rossi,et al.  Serum posaconazole levels during acute myeloid leukaemia induction therapy: correlations with breakthrough invasive fungal infections , 2015, Mycoses.

[17]  A. Guarascio,et al.  Review of the New Delayed‐Release Oral Tablet and Intravenous Dosage Forms of Posaconazole , 2015, Pharmacotherapy.

[18]  R. Porcher,et al.  Breakthrough invasive fungal disease in patients receiving posaconazole primary prophylaxis: a 4-year study. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[19]  D. Kontoyiannis,et al.  Switching from Posaconazole Suspension to Tablets Increases Serum Drug Levels in Leukemia Patients without Clinically Relevant Hepatotoxicity , 2014, Antimicrobial Agents and Chemotherapy.

[20]  Jong Hun Kim,et al.  Posaconazole Salvage Treatment for Invasive Fungal Infection , 2014, Mycopathologia.

[21]  H. Waskin,et al.  Posaconazole Tablet Pharmacokinetics: Lack of Effect of Concomitant Medications Altering Gastric pH and Gastric Motility in Healthy Subjects , 2014, Antimicrobial Agents and Chemotherapy.

[22]  L. Pagano,et al.  ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[23]  G. Egerer,et al.  Posaconazole after previous antifungal therapy with voriconazole for therapy of invasive aspergillus disease, a retrospective analysis , 2013, Mycoses.

[24]  C. Ferraz,et al.  Posaconazole as rescue therapy in African histoplasmosis , 2013, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

[25]  G. Gastl,et al.  Invasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in high-risk patients receiving antifungal prophylaxis with posaconazole: real-life data from a single-centre institutional retrospective observational study. , 2012, The Journal of antimicrobial chemotherapy.

[26]  A. McLachlan,et al.  Multicenter Study of Posaconazole Therapeutic Drug Monitoring: Exposure-Response Relationship and Factors Affecting Concentration , 2012, Antimicrobial Agents and Chemotherapy.

[27]  Xiao-jun Huang,et al.  A multicenter, open-label study of posaconazole oral suspension in the treatment of invasive fungal infections in patients refractory to or intolerant of first-line therapy. , 2012, Future microbiology.

[28]  C. Lass‐Flörl.  Triazole Antifungal Agents in Invasive Fungal Infections , 2011, Drugs.

[29]  G. Krishna,et al.  Pharmacokinetics and Absorption of Posaconazole Oral Suspension under Various Gastric Conditions in Healthy Volunteers , 2008, Antimicrobial Agents and Chemotherapy.

[30]  J. S. Daly,et al.  Posaconazole as Salvage Therapy in Patients With Invasive Fungal Infections After Solid Organ Transplant , 2008, Transplantation.

[31]  Patricia Muñoz,et al.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  D. Kontoyiannis,et al.  Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin , 2008, Leukemia.

[33]  M. Seibold,et al.  Successfully treated Candida krusei infection of the lumbar spine with combined caspofungin/posaconazole therapy. , 2008, Medical mycology.

[34]  J. Perfect,et al.  Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  D. Kontoyiannis,et al.  Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  M. Schuster,et al.  Posaconazole as Salvage Therapy for Zygomycosis , 2006, Antimicrobial Agents and Chemotherapy.

[37]  C. Banfield,et al.  Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. , 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[38]  J. Meis,et al.  In vitro susceptibilities of zygomycetes to conventional and new antifungals. , 2003, The Journal of antimicrobial chemotherapy.

[39]  D. Loebenberg,et al.  In Vivo Activity of Posaconazole against Mucor spp. in an Immunosuppressed-Mouse Model , 2002, Antimicrobial Agents and Chemotherapy.

[40]  J. Graybill,et al.  In Vitro Activities of Posaconazole, Itraconazole, Voriconazole, Amphotericin B, and Fluconazole against 37 Clinical Isolates of Zygomycetes , 2002, Antimicrobial Agents and Chemotherapy.